rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    LYEL
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Lyell Immunopharma at Stifel 2026 Healthcare Conference: ronde-cel push
      Nov 10Investing.comLYEL
      Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy
      Nov 6Yahoo FinanceLYEL
      Lyell: Upgrade To 'Buy' On Ronde-Cel Advancement LBCL And $80 Million Funding Boost
      Nov 5Seeking AlphaLYEL
      Lyell Immunopharma: Q3 Earnings Snapshot
      Nov 4Yahoo FinanceLYEL
      Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
      Nov 4Yahoo FinanceLYEL
      Lyell reports trial data for ronde-cel lymphoma treatment
      Nov 4Investing.comLYEL
      Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
      Nov 4Yahoo FinanceLYEL
      Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
      Nov 4Yahoo FinanceLYEL
      Baird reiterates Lyell Immunopharma stock rating ahead of data
      Nov 2Investing.comLYEL
      Lyell Immunopharma To Participate in November Investor Events
      Nov 2Yahoo FinanceLYEL
      Copper squeeze breathes new life into old mines
      Oct 15ReutersLYELSBSW
      Lyell Immunopharma CMO sells $3,641 in shares for tax withholding
      Oct 14Investing.comLYEL
      Down 27% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
      Oct 13Yahoo FinanceLYEL
      Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
      Sep 14Yahoo FinanceLYEL
      H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy
      Sep 11Investing.comLYEL
      Lyell Immunopharma CMO David Shook sells $6,350 in shares
      Sep 11Investing.comLYEL
      Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting
      Sep 10Investing.comLYEL
      Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

      Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDAAdditional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal c

      Sep 10Yahoo FinanceLYEL

      This is the newest page. Registered accounts read further back.